results

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Conference Call October 20, 8:45am ESTQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment…

1 month ago

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Conference Call October 20, 8:45am ESTQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment…

1 month ago

Akums Reports Q4 FY25 with 12.4% Revenue Growth, FY25 Adj. EBITDA Remained Strong at 12.3%

Akums Drugs and Pharmaceuticals Ltd., India’s largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for…

1 month ago

Synaptics to Report First Quarter Fiscal 2026 Results on November 6, 2025

SAN JOSE, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: SYNA) today announced that it will report financial results…

1 month ago

Starburst Announces Winners of the 2025 Data Visionary Awards

Awards honor customers and partners who are redefining what's possible with data and AI BOSTON, Oct. 14, 2025 /PRNewswire/ --…

1 month ago

Euro NCAP to Launch New 2025 Car Safety Results

WhatLatest Euro NCAP results published online and via social media.WhenWednesday 15 October - 11:00 a.m. CEST.WhereGo to Euro NCAP's Press Releases or…

1 month ago

EverQuote to Announce Third Quarter 2025 Financial Results on November 3, 2025

October 13, 2025 16:10 ET  | Source: EverQuote, Inc. CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- EverQuote, Inc. (Nasdaq:…

1 month ago

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies…

1 month ago

NTG Nordic Transport Group A/S – Q3 2025 Conference Call

October 10, 2025 04:00 ET  | Source: NTG Nordic Transport Group A/S NTG Nordic Transport Group A/S – Q3 2025…

2 months ago

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinsons disease

Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants Secondary…

2 months ago